News | August 06, 2025
Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Athena is also exploring the use of this technology for expanded carrier screening
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
To streamline complex medical writing workflows with GenAI
Most recently he served as Chief Operating Officer at Bharat Serums and Vaccines
Subscribe To Our Newsletter & Stay Updated
